By using CO2 processes for drug isolation, purification and formulation we create improved pharmaceutical products. Through our unique formulation technology, especially encapsulation, we create targeted and triggered release systems. The combination with an active ingredients often leads to patent applications increasing the life span of a drug.
An increased bioavailability can be obtained by creating a large surface area through micronization or a molecular formulation using our CO2 spray dry technology. This increased bioavailability will enable you to decrease the amount of active ingredients which goes hand in hand with increasing patent life. Increased product shelf-life achieved by protecting for instance the active ingredient by UV coating or moisture protecting coatings. Our CO2 technology is performed below 60⁰C and leaves no residual solvents, which makes it suitable for peptide proteins and enzymes.
Not only can we conduct the development of the technology, but we can also make clinical batches. Since 2006 we hold a pharma GMP license. Our team has experience with clinical trials, from phase I, IIA/IIB up to phase III. Production can be conducted by our team using our GMP facilities.
Due to the fact that CO2 is especially suitable for non-polar molecules, we have gained extensive knowledge on psylocibin is hydrophilic and is psychoactive. This is why we have had an opiate license since 2002 and are able to handle cannabinoids and psychedelics, among other compounds.